Literature DB >> 10403400

The combination of polymorphisms within interferon-gamma receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus.

H Nakashima1, H Inoue, M Akahoshi, Y Tanaka, K Yamaoka, E Ogami, S Nagano, Y Arinobu, H Niiro, T Otsuka, Y Niho.   

Abstract

Genetic factors seem to play a significant role in susceptibility to systemic lupus erythematosus (SLE). We previously described the amino acid polymorphism (Val14Met) within the IFN-gamma receptor 1 (IFN-gammaRI), and that the frequency of the Metl4 allele in SLE patients was significantly higher than that of the healthy control population [Tanaka et al. (1999) Immunogenetics 49, 266-271]. We also found an amino acid polymorphism (Gln64Arg) within IFN-gamma receptor 2 (IFN-gammaR2). Since the IFN-gamma receptor is a complex consisting of IFN-gammaR1 and IFN-gammaR2, we searched for the particular combination of two kinds of amino acid polymorphisms found within the IFN-gamma receptor which plays a prominent role in susceptibility to SLE. The greatest risk of the development of SLE was detected in the individuals who had the combination of IFNGR1 Met14/Val14 genotype and IFNGR2 Gln64/Gln64 genotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403400     DOI: 10.1016/s0014-5793(99)00701-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

Review 1.  Biomarkers in systemic lupus erythematosus.

Authors:  Gabor G Illei; Peter E Lipsky
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 2.  Current topics in human SLE genetics.

Authors:  Maida Wong; Betty P Tsao
Journal:  Springer Semin Immunopathol       Date:  2006-08-29

3.  Expression of Interferon-γ Receptor Genes in Peripheral Blood Mononuclear Cells Is Associated With Rheumatoid Arthritis and Its Radiographic Severity in African Americans.

Authors:  Qi Tang; Maria I Danila; Xiangqin Cui; Lauren Parks; Brandi J Baker; Richard J Reynolds; Chander Raman; Keith C Wanseck; David T Redden; Martin R Johnson; S Louis Bridges
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

4.  Th2 skewing by activation of Nrf2 in CD4(+) T cells.

Authors:  Cheryl E Rockwell; Mingcai Zhang; Patrick E Fields; Curtis D Klaassen
Journal:  J Immunol       Date:  2012-01-16       Impact factor: 5.422

5.  Association of interferon-gamma gene polymorphism (+874A) with arthritis manifestation in SLE.

Authors:  Marut Tangwattanachuleeporn; Pimpayao Sodsai; Yingyos Avihingsanon; Jongkonnee Wongpiyabovorn; Jeerapat Wongchinsri; Nattiya Hirankarn
Journal:  Clin Rheumatol       Date:  2007-08-23       Impact factor: 2.980

6.  Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritis.

Authors:  Andrea Fava; Jill Buyon; Chandra Mohan; Ting Zhang; H Michael Belmont; Peter Izmirly; Robert Clancy; Jose Monroy Trujillo; Derek Fine; Yuji Zhang; Laurence Magder; Deepak A Rao; Arnon Arazi; Celine C Berthier; Anne Davidson; Betty Diamond; Nir Hacohen; David Wofsy; William Apruzzese; Soumya Raychaudhuri; Michelle Petri
Journal:  JCI Insight       Date:  2020-06-18

7.  IFNGR1 single nucleotide polymorphisms in rheumatoid arthritis.

Authors:  Stefan Mattyasovszky; Alla Skapenko; Joachim R Kalden; Peter E Lipsky; Hendrik Schulze-Koops
Journal:  Arthritis Res Ther       Date:  2006-03-23       Impact factor: 5.156

8.  The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity.

Authors:  A N Theofilopoulos; S Koundouris; D H Kono; B R Lawson
Journal:  Arthritis Res       Date:  2001-02-14

9.  Lupus-prone mice fail to raise antigen-specific T cell responses to intracellular infection.

Authors:  Linda A Lieberman; George C Tsokos
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

Review 10.  Current status of lupus genetics.

Authors:  Andrea L Sestak; Swapan K Nath; Amr H Sawalha; John B Harley
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.